Abstract
The lecture analyses current tools of anti-inflammatory treatment of patients with chronic obstructive pulmonary disease (COPD). Anti-inflammatory treatment is aimed at a key element of COPD pathogenesis. The results of treatment with main anti-inflammatory drugs and methods in COPD management are reviewed as well as efficacy of a new anti-inflammatory drug roflumilast in COPD patients.
MeSH terms
-
Aminopyridines / administration & dosage
-
Aminopyridines / therapeutic use*
-
Anti-Inflammatory Agents, Non-Steroidal / administration & dosage
-
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
-
Benzamides / administration & dosage
-
Benzamides / therapeutic use*
-
Cyclic Nucleotide Phosphodiesterases, Type 4 / biosynthesis
-
Cyclopropanes / administration & dosage
-
Cyclopropanes / therapeutic use
-
Humans
-
Leukocytes / drug effects
-
Leukocytes / enzymology
-
Phosphodiesterase 4 Inhibitors / administration & dosage
-
Phosphodiesterase 4 Inhibitors / therapeutic use*
-
Pulmonary Disease, Chronic Obstructive / drug therapy*
-
Pulmonary Disease, Chronic Obstructive / enzymology
-
Treatment Outcome
Substances
-
Aminopyridines
-
Anti-Inflammatory Agents, Non-Steroidal
-
Benzamides
-
Cyclopropanes
-
Phosphodiesterase 4 Inhibitors
-
Roflumilast
-
Cyclic Nucleotide Phosphodiesterases, Type 4